Ipamorelin – Selective GHS-R Agonist (Research Use Only)

Ipamorelin – Selective GHS-R Agonist (Research Use Only)

Peptide Research Documentation · For Research Use Only

Peptide Research Documentation

Ipamorelin – Research Documentation Overview

Neutral, research-only summary for laboratories and qualified organizations exploring selective GHS-R agonist compounds in non-clinical models.

For Research Use Only. Ipamorelin (NNC 26-0161, Aezs-108 peptide) is a synthetic pentapeptide (Aib-His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂) intended exclusively for in vitro and non-clinical in vivo research. This compound is not approved for human consumption, medical use, or veterinary application.

At a Glance

Ipamorelin is a potent, selective GHS-R1a (growth hormone secretagogue receptor 1a) agonist with reported selectivity advantages over GHRP-2 and GHRP-6, exhibiting minimal prolactin, cortisol, and acetylcholine agonism. Developed by Novo Nordisk in the 1990s and extensively published in preclinical literature, ipamorelin demonstrates robust GH secretagogue activity in rodent and primate models with a favorable safety margin in long-term dosing studies. The pentapeptide backbone (incorporating α-aminoisobutyric acid) confers resistance to enzymatic degradation and oral bioavailability.

Document Objectives

  • Define molecular structure, GHS-R selectivity profile, and pharmacological mechanism
  • Establish storage conditions, stability parameters, and reconstitution protocols
  • Outline documentation requirements for research use and regulatory compliance
  • Review representative non-clinical models: acute GH secretion, body composition, aging
  • Address risk assessment, purity standards, and institutional oversight requirements

Storage & Stability

Optimal Storage Conditions

Ipamorelin lyophilized powder exhibits maximal stability when stored at -20°C to -80°C in airtight, light-resistant containers. For research programs with extended storage requirements (>12 months), -80°C freezer storage is strongly recommended. The pentapeptide backbone, including the α-aminoisobutyric acid (Aib) substitution, provides good resistance to protease degradation, but room-temperature storage remains unsuitable due to oxidative degradation and moisture-driven aggregation.

Lyophilized Product Stability

Unopened vials maintain potency throughout the supplier-specified shelf-life (typically 18–24 months) when stored in original packaging at -20°C or below. Upon receipt, confirm powder appearance: a white to pale beige lyophilisate indicates proper handling. Any visible discoloration, clumping, or moisture suggests prior temperature excursion or humidity exposure; such material should be rejected. Once reconstituted, aqueous solutions (0.1–50 mM) in sterile saline or PBS remain stable for 2–3 weeks at 4°C under aseptic conditions.

Environmental Controls & Preservation

Maintain storage containers in desiccated environments using vacuum-sealed bags or desiccant packets. Minimize light exposure through use of amber vials or foil-wrapped outer packaging. Relative humidity during storage should remain <50% to prevent hygroscopic moisture absorption. Avoid repeated freeze-thaw cycles, which compromise peptide integrity; instead, prepare small aliquots for single-use and discard unused portions after thawing.

Handling & Aliquoting

Preparation & Dissolution Protocol

Weigh ipamorelin lyophilized powder using a calibrated analytical balance (±0.001 g precision). Dissolve in sterile, endotoxin-free saline (0.9% NaCl), 1× phosphate-buffered saline (PBS), or cell culture medium (e.g., DMEM, Neurobasal) depending on experimental application. Allow 20–30 minutes at ambient temperature for complete dissolution, stirring gently if necessary; excessive heating accelerates peptide thermal denaturation and should be avoided. For animal study solutions, use USP-grade parenteral vehicles (sterile water for injection, normal saline) prepared under aseptic conditions.

Aliquoting & Inventory Management

Prepare stock solutions (1–10 mM) and divide into sterile, low-binding microtubes (100–500 μL per aliquot) using laminar flow hood aseptic technique. Label each tube with: compound name (ipamorelin), lot number, date of preparation, final concentration, and expiration. Working solutions prepared for animal dosing should be freshly prepared or stored at 4°C for a maximum of 48 hours prior to use. Maintain a master aliquot log in both electronic and hardcopy formats, tracking all uses and final dispositions.

Aseptic Technique & Quality Assurance

All handling of ipamorelin solutions must adhere to GLP aseptic technique standards. Use only sterile, pyrogen-free pipette tips, microtubes, and syringes. For intravenous or subcutaneous animal dosing, filter-sterilize solutions through 0.22 μm syringe filters immediately before administration. Inspect all prepared solutions for visible particulates, cloudiness, or discoloration; discard any compromised batches. Document final volumes and concentrations of all preparations, and perform periodic microbial monitoring (sterile filtration validation) if solutions are stored beyond 1 week.

Documentation Checklist

Core Documentation Requirements

Archival & Audit Standards

Maintain dual archival of all CoA certificates, analytical reports, and stability documentation in both hard-copy and encrypted electronic formats. For studies exceeding 6 weeks duration, perform periodic potency verification (HPLC analysis or bioassay) of stored working solutions to rule out degradation and validate stability assumptions. Document any deviations from expected appearance or behavior and conduct root-cause analysis.

Example Non-Clinical Models

Acute GH Secretion in Rodents

Ipamorelin (0.05–10 mg/kg, SC or IP) induces dose-dependent, rapid GH release in conscious rats and mice with peak plasma GH elevation at 15–45 minutes post-dosing. Response is receptor-mediated (inhibited by GHS-R1a antagonists) and synergistic with GHRH. Microdialysis probes in pituitary stalk tissue have characterized GH-releasing hormone (GHRH) co-release. Tail-vein or cardiac blood sampling at 5, 15, 30, 60, and 120 minute intervals captures kinetic GH profiles.

Long-term Body Composition & Metabolism Studies

Chronic ipamorelin dosing (0.1–2 mg/kg/day for 4–16 weeks, SC injection) in rodent obesity models, aging studies, and transgenic disease models has been evaluated for effects on lean mass, fat mass distribution, whole-body energy expenditure, and metabolic markers (serum IGF-1, insulin, glucose). Representative models include high-fat diet-induced obesity, Zucker fa/fa leptin-deficient rats, and aged (18–24 month) Fisher-344 rats, with outcomes including MRI body composition, indirect calorimetry, and necropsy-derived organ analysis.

GH Pulse Architecture & Somatotroph Sensitivity

Repeated (chronic) ipamorelin administration has been evaluated in accelerated aging models and long-term GH deficiency contexts for preservation or restoration of GH pulse frequency, amplitude, and somatotroph responsiveness. Studies often employ frequent blood sampling (q10 min, 6–12 hour periods) to quantify GH pulse parameters via deconvolution analysis. Pituitary ex vivo culture systems assess somatotroph GH secretory capacity and receptor expression changes.

Selectivity & Safety Pharmacology

Comparative studies (ipamorelin vs. GHRP-2, GHRP-6, or ghrelin) at equipotent GH-releasing doses demonstrate ipamorelin’s reduced stimulation of prolactin, ACTH/cortisol, and GI motility. In vitro transfected cell systems (HEK293 with GHS-R, melanocortin, or histamine H1 receptors) confirm GHS-R1a selectivity (EC₅₀ 0.5–5 nM) and minimal off-target agonism. Long-term toxicology studies (13–52 weeks, IV or SC dosing) in rodents and dogs assess organ toxicity, pathology, and hematologic/clinical chemistry changes at multiples of pharmacologically active doses.

Compliance & Risk Notes

Regulatory Status & Legal Framework

Ipamorelin is not approved by the FDA, EMA, PMDA, or other major regulatory authorities for human therapeutic use. No marketed pharmaceutical products contain ipamorelin. As a research compound, it typically falls outside GMP pharmaceutical requirements but should be procured from suppliers maintaining GLP-aligned quality standards, analytical method validation, and comprehensive documentation. Academic and contract research organizations (CROs) using ipamorelin must maintain GLP-compliant operational standards for studies supporting regulatory submissions.

Safety Considerations & Hazard Assessment

Ipamorelin lyophilized powder presents minimal acute inhalation, dermal, or ocular hazard at typical laboratory quantities. Aqueous solutions are non-irritating to mucous membranes at physiological concentrations (≤100 μM). Standard laboratory PPE (nitrile gloves, laboratory coat) and engineering controls (fume hood for weighing) provide appropriate protection. In animal studies, parenteral injection carries routine risks (localized irritation, infection); strict aseptic technique, use of sterile syringes, and injection site monitoring minimize adverse events. Reported GH hyperstimulation side effects from long-term dosing (edema, carpal tunnel syndrome) are relevant only in clinical contexts and not expected in short-term non-clinical research dosing.

Data Integrity & Regulatory Readiness

Establish comprehensive, written SOPs for ipamorelin receipt, storage, aliquoting, dosing, and archival. Implement unique lot identifiers for all compound batches and aliquots. Maintain synchronized hardcopy and electronic records documenting all compound use, with clear chain-of-custody documentation linking lot numbers to specific experiments. Ensure IACUC protocol approval for all animal studies and maintain compliance with institutional animal care standards. Archive all research data (raw data, analysis, final reports) for a minimum of 7 years to support regulatory audit readiness if studies contribute to IND submissions or regulatory dossiers.

References & Evidence Snapshot

Key Scientific Literature

Evidence Summary

Ipamorelin is one of the most extensively characterized synthetic GH secretagogues in preclinical literature, with robust evidence for GHS-R1a-mediated GH secretion in rodent, canine, and primate non-clinical models. Key advantages over GHRP-2 and GHRP-6 include superior GHS-R selectivity, reduced off-target hormone stimulation (prolactin, ACTH), and favorable long-term safety and tolerability in chronic dosing studies. Mechanistic studies confirm calcium-dependent exocytosis in somatotrophs, synergistic effects with GHRH, and preservation of GH pulse architecture in aging contexts. Long-term body composition and metabolic studies support ipamorelin’s utility for investigating GH-dependent anabolic processes in rodent obesity and aging models, though translation of findings to human physiology requires careful experimental design and consideration of species-specific GH biology.

← Back to Peptide Research Index

Questions About This Compound?

Our clinical team can help with research documentation and protocol guidance.

Contact Our Team

Disclaimer: This content is for research documentation purposes only. Not for human consumption or therapeutic application.

GLP3 Weight Loss

Customer Support

Get in touch with our team today.

  • +1757-618-2938
  • info@glp3weightloss.com

    Get Update & More

    Subscribe to our free newsletter and get 15% discount in your next order.

    SIGN UP NOW

    Copyright © 2025 GLP3 Weight Loss.